Bone Research Society

BRS Annual Meeting 2024


Wednesday 10 - Friday 12 July 2024

Sheffield, UK

Exhibition & Sponsorship

 

The BRS 2024 annual meeting will attract around 200 delegates from across the country and beyond.  Exhibiting at our meeting will give you access to leading experts in the field of Bone Research.  The exhibition will be held in the main Dining Hall on the ground floor of the Edge where posters and catering are integrated allowing for a central area for networking.

You can find more detailed information about the Sponsorship opportunities available HERE.  

We wish to thank the following industry partners for their confirmed support to the BRS Annual Meeting 2024.

 

SILVER SPONSORS

Alexion, AstraZeneca Rare Disease, is the group within AstraZeneca focused on rare diseases, created following the 2021 acquisition of Alexion Pharmaceuticals, Inc. As a leader in rare diseases for 30 years, Alexion is focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development and commercialisation of life-changing medicines.  Alexion focuses its research efforts on novel molecules and targets in the complement cascade and its development efforts on haematology, nephrology, neurology, metabolic disorders, cardiology, and ophthalmology. Headquartered in Boston, Massachusetts, Alexion has offices around the globe and serves patients in more than 50 countries.
M/UK/UNB-U/0219 March 2023

 

Alexion Sponsored Satellite Symposium (part of the Rare Bone Diseases Session) 

Wednesday 10 July 2024 (17:30-18:00)

Advances in Hypophosphatasia care - Professor Richard Keen - Consultant in Metabolic Bone Disease (Royal National Orthopaedic Hospital, Stanmore, UK

 

Kyowa Kirin strives to create and deliver novel medicines with life-changing value. As a Japan-based Specialty Pharmaceutical Company with a heritage of 70+ years, we apply cutting-edge science including an expertise in antibody research and engineering, to address the needs of patients and society across multiple therapeutic areas including Nephrology, Oncology, Immunology/Allergy and Neurology. Across our four regions – Japan, Asia Pacific, North America and EMEA/International – we focus on our purpose, to make people smile, and are united by our shared values of commitment to life, teamwork/Wa, innovation, and integrity.

You can learn more about the business of Kyowa Kirin at: https://international.kyowa-kirin.com/uk/

 

Kyowa Kirin Sponsored Satellite Symposium  

Thursday 11 July 2024 (14:55-15:40)

Chair: Professor Richard Keen (Stanmore, UK)

OPTIMISING CARE FOR ADULTS WITH RARE METABOLIC BONE CONDITIONS: A NETWORK APPROACH

Speakers and Expert Panel:

Dr Gavin Clunie - Consultant Rheumatologist and Metabolic Bone Physician (Cambridge University Hospitals NHS Foundation Trust) 

Dr Judith Bubbear - Consultant in Metabolic Bone Diseases (Royal National Orthopaedic Hospital NHS Trust) 

Professor Kassim Javaid - Consultant Rheumatologist (Oxford University NHS Foundation Trust)

Full details about this sponsored symposium can be found HERE

 

BRONZE SPONSORS

 

At 10x Genomics we have 3 tools to address your experimental needs. These include our single cell platform which allows transcriptomic profiling of up to a million single cells with multiomic capabilities to reveal cellular diversity. Our spatial discovery platform which enables whole transcriptome analysis of FFPE and Fresh Frozen tissue within morphological context, and finally our spatial imaging platform which maps RNA molecules with subcellular resolution in tissue sections for a deeper look into cellular mechanisms or interactions. Our spatial imaging platform is capable of performing analysis on soft tissue derived from bone without any protocol modifications, analysing these samples in unprecedented detail.

Reach out to your local 10x rep for further details on how these platforms might fit into your workflow.

Company URL: https://www.10xgenomics.com/

Bone Specific URL: https://kb.10xgenomics.com/hc/en-us/articles/21861808009485-Is-bone-derived-soft-tissue-compatible-with-Xenium-In-Situ-Gene-Expression

 

BlueScientific is a distributor of market-leading scientific instrumentation for research, development and process control in both the academic and industrial markets across the UK, Ireland and Nordic region (Denmark, Sweden, Finland, Iceland and Norway).

We are the official distributor of Bruker's range of X-Ray Microscopes (XRM), also known as Micro-CT.  Micro-CT is a non-destructive 3D imaging and analysis technique. It can be used to examine the internal structure of a huge variety of samples. Using the same method as hospital CT scans, but on a smaller scale with dramatically increased resolution. The results represent 3D microscopy, revealing the internal structures of objects at a very fine scale.

For bone research, micro-CT is faster than histology or slicing. Acquire a scan in 10-15 minutes (medium resolution) or a few hours (high resolution) and generate 3D reconstructions in minutes.

In dental applications, microtomography delivers fine, highly detailed images at micrometre scale. It’s non-destructive, so you can take multiple scans, as well as virtual slices and flights through your sample. 

Our website address is: https://blue-scientific.com/

 

CompagOs, a Swiss startup from ETH Zürich, develops diagnostic and research tools utilizing 3D-bioprinted, mineralized, and multicellular in vitro bone models.

https://www.compagos.ch

 

Inozyme Pharma is a rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases driven by pathologic mineralization and intimal proliferation which impact the vasculature, soft tissue and skeleton.

We are initially focused on developing an enzyme therapy to treat ENPP1 and ABCC6 Deficiencies, rare genetic diseases associated with significant morbidity, mortality, and unmet medical need.

Please get in touch if you encounter potential subjects for our clinical trials program.

 

MILabs is a global leader in the development high-performance preclinical CT, optical and nuclear imaging systems.  The micro-CT scanners provide outstanding resolution (12um), low dose imaging capabilities (<2mGy), and fast scanning (<5s). This high-performance micro-CT is also an integrated part of MILabs’ multimodal SPECT/CT, PET/CT, Optical/CT, and PET/SPECT/CT  systems. The imaging systems are built in different custom configurations to best meet the researcher’s needs, offering exceptional performance, cost-effectiveness, and reliability. Whether offered as stand-alone units or in multimodal imaging configurations, MILabs is pushing the performance limits in terms of image quality and functionality.

 

Please do visit our website for more information - link the webpage is www.scanco.ch

 

We are Theramex, a global speciality pharmaceutical company solely committed to supporting the health needs of women through every stage of life. We work on patient-focused, effective solutions that support women of all ages.

We work closely with our partners, healthcare professionals, and patients to provide women with the right solution, at the time they most need it.

We believe in empowering women to make informed decisions about how to manage the natural cycles and stages of their life. To do this, we provide education and support around contraception, fertility and menopause.

 

 

 

Wonderful Scientific is the proud distributor of Neoscan.com benchtop Micro-CT products in the UK and Ireland.  The N80 scanner is the best in class scanner and is ideal for high resolution bone analysis and visualisation of osteocyte lacunae.  The N80 has a sealed transmission X-ray source with a 2um spot size and movable target repositioning, radiation hardened camera protection, 2: fibre optics, active artefact suppression, new precision stepper motors and all new software.  The resulting benefits make it the most robust, long lasting, advanced and highest resolution benchtop Micro-CT on the market today.

 

RARE BONE DISEASE SESSION SPONSORS

Alexion, AstraZeneca Rare Disease, is the group within AstraZeneca focused on rare diseases, created following the 2021 acquisition of Alexion Pharmaceuticals, Inc. As a leader in rare diseases for 30 years, Alexion is focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development and commercialisation of life-changing medicines.  Alexion focuses its research efforts on novel molecules and targets in the complement cascade and its development efforts on haematology, nephrology, neurology, metabolic disorders, cardiology, and ophthalmology. Headquartered in Boston, Massachusetts, Alexion has offices around the globe and serves patients in more than 50 countries.
M/UK/UNB-U/0219 March 2023

 

Alexion Sponsored Satellite Symposium (part of the Rare Bone Diseases Session) 

Wednesday 10 July 2024 (17:30-18:00)

Advances in Hypophosphatasia care - Professor Richard Keen - Consultant in Metabolic Bone Disease (Royal National Orthopaedic Hospital, Stanmore, UK

 

Kyowa Kirin strives to create and deliver novel medicines with life-changing value. As a Japan-based Specialty Pharmaceutical Company with a heritage of 70+ years, we apply cutting-edge science including an expertise in antibody research and engineering, to address the needs of patients and society across multiple therapeutic areas including Nephrology, Oncology, Immunology/Allergy and Neurology. Across our four regions – Japan, Asia Pacific, North America and EMEA/International – we focus on our purpose, to make people smile, and are united by our shared values of commitment to life, teamwork/Wa, innovation, and integrity.

You can learn more about the business of Kyowa Kirin at: https://international.kyowa-kirin.com/uk/

 

 

Mereo is an agile biotech company, focused on finding, developing and bringing to market therapies that will improve the lives of people living with rare conditions. 

We are driven by a true understanding of the critical nature of our mission and we combine three core elements to create new possibilities for patients who need new treatment options: the power of science; our knowledge of the rare diseases we seek to treat; and our daily commitment to develop deep, durable and authentic relationships with all our stakeholders.

Central to every decision and action at Mereo are the communities that we are here to serve. Each member of our team is committed to building personal understanding about what will make a real difference to those communities and to bring this understanding back to our shared work together to deliver new treatments in a timely and sustainable way.

www.mereobiopharma.com

 

 

AND THANK YOU TO OUR FINAL SUPPORTER

 

The Bone Cancer Research Trust is the leading charity dedicated to fighting primary bone cancer; we are uniquely placed to make a difference through research, information, awareness, and support. 

We aim to be a catalyst for pioneering research that saves lives and improves outcomes for patients with primary bone cancer, supporting much-needed advancements towards kinder, more targeted treatments. We therefore offer a diverse range of research grants for researchers at all stages in their career, with interests directly or indirectly aligned to primary bone cancer. This encompasses a wide variety of disciplines, and we are proud to fund researchers and clinicians with expertise in bone disease and biology, chemistry, biomaterials, medical engineering, pathology, and much more. 

Our grant programme ranges from small scale Idea Grants and funding for research meetings, to larger scale Research Projects, Translational Grants, PhD Studentships, Early Career Fellowships and Consortia funding.

This year, we are delighted to offer Skills Development Grants up to £300 for delegates attending the Bone Research Society Annual Meeting 2024. Our Skills Development Grants support UK-based researchers to travel nationally & internationally, attending conferences, courses, and laboratories, providing them with vital skills development and networking opportunities.

For further information, please contact research@bcrt.org.uk.

 

For further information and queries about sponsorship and exhibiting opportiunities, please contact the BRS Event Team:

events@boneresearchsociety.org